摘要
目的评价国产火鸟支架(F ireb ird支架)在冠心病患者中临床应用的近、远期疗效。方法在2004年1月至2005年4月期间,我院共有194名冠心病患者植入F ireb ird支架,其中单支血管病变患者90例,两支血管病变患者75例,三支血管病变患者29例。在所有病变中,弥漫性病变87例(44.8%)、分叉病变63例(32.5%)、慢性完全闭塞性病变36例(18.6%)、小血管病变19例(9.8%),钙化病变17例(8.8%),开口部病变15例(7.7%)。术前、术后常规使用抗血小板药物及治疗冠心病药物,观察F ireb ird支架植入的手术成功率、术中并发症、住院期间及6个月临床随访期间的心血管事件和再狭窄发生率。结果支架植入成功率为100%,术中和住院期间死亡2例,心肌梗死2例,住院期间主要心脏不良事件发生率为1.5%,192例患者随访6个月,1例死于脑出血,1例猝死,2例进行了靶血管重建,主要心脏不良事件发生率为2.1%。冠状动脉造影再狭窄率为4.3%,靶病变重建率为1.09%。结论国产F ireb ird支架是安全和有效的,其支架内再狭窄率仍明显低于普通金属支架。
Objective To evaluate the short and long term clinical outcome of Firebird drug - during stent in patients with coronary disease. Methods From January 2004 to April 2005, Firebird drug - eluting sten was implanted in 194 palients. Among them, 90 had single vessel disease, 75 double vessel disease and 29 triple vessel diseasl. As for lesion characteristics, diffuse disease was found in 87 cases （44.8%） , difureation lesions in 63 cases （32.5%） , chronic total occlusion lesions in 36 cases, （ 18.6% ） , small vessel lesions in 19 cases（9.8% ） , calcified lesions in 17 cases （8.8 % ）, and ostial lesions in 15 cases （7.7 % ）. Antithrombotic drugs and drugs for coronary artery disease were conventionally used before and affter the procedure. Success rate , complication in the procedure, major cardiac event during hospital were observed, both major cardiac event and restenosis were observed at a 6 - months follow - up. Results Success rate of stent implantation was 100%. There was 2 death during the procedure and hospitalization, one died from malignant arrhythmia, the other died from cardiac shock. AM1 occurred in 2 patients. The major cardiac event （MACE） rate was 1.5%. During the follow - up period, Death occurred in two patients （ one died from cerebral hemorrhage, the other from sudden death and target vessel revascularization （TLR） was performed in 2 patients, with a MACE rate of 2.1%. Angiographic follow - up for six months showed that ISR rate was 4.3% , TLR rate was 1.09%. Conclusion Firebird drug - ing stent implantation is safe and effective when used in the patients with coronary disease. ISR rate is still significantly lower than than of bare metal stents.
出处
《临床和实验医学杂志》
2006年第3期205-206,共2页
Journal of Clinical and Experimental Medicine
